SCHEMBL29327658

SCHEMBL29327658

CCc1ccc(-c2nc3cc(NC(=O)c4nc(C#N)ccc4S(C)(=O)=O)ccc3n2C)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 3/20 0.52
▸ PTGES O14684 2/20 0.46
▸ RAB9A P51151 5/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ AGPAT2 O15120 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ HDAC1 Q13547 2/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ HDAC6 Q9UBN7 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327654 0.93 PPARG (0.52) PPARGPTGESRAB9ANPC1TP53
SCHEMBL29327781 0.86 PPARG (0.54) PPARGPTGESRAB9ANPC1AGPAT2
SCHEMBL29327609 0.86 PPARG (0.55) PPARGPTGESRAB9ANPC1AGPAT2
SCHEMBL29327949 0.82 HDAC6 (0.48) PPARGRAB9ANPC1MAPTHDAC1
SCHEMBL29327625 0.81 PPARG (0.60) PPARGRAB9ANPC1MAPTPOLB
SCHEMBL29327950 0.80 MAPT (0.50) RAB9ANPC1MAPTHDAC6POLB
SCHEMBL29327651 0.80 PPARG (0.51) PPARGRAB9ANPC1MAPTPOLB
SCHEMBL29327775 0.79 PPARG (0.54) PPARGPTGESRAB9ANPC1MAPT
SCHEMBL29327607 0.79 PPARG (0.55) PPARGPTGESRAB9ANPC1MAPT
SCHEMBL29327944 0.79 ATR (0.40) PPARGRAB9ANPC1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885PTGES 139/4885RAB9A 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback